Immunocore Financial Statements From 2010 to 2026

IMCR Stock  USD 30.86  1.21  3.77%   
Immunocore Holdings' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Immunocore Holdings' valuation are provided below:
Gross Profit
334.4 M
Profit Margin
(0.08)
Market Capitalization
1.6 B
Enterprise Value Revenue
3.0665
Revenue
379.6 M
There are over one hundred nineteen available fundamental trends for Immunocore Holdings, which can be analyzed over time and compared to other ratios. Investors and active traders are advised to confirm Immunocore Holdings' regular fundamental performance against the performance between 2010 and 2026 to make sure the trends are evolving in the right direction. As of 02/05/2026, Market Cap is likely to grow to about 3.2 B. Also, Enterprise Value is likely to grow to about 2.8 B

Immunocore Holdings Total Revenue

299.18 Million

Check Immunocore Holdings financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Immunocore Holdings' main balance sheet or income statement drivers, such as Interest Expense of 22.8 M, Other Operating Expenses of 367.1 M or Net Interest Income of 8.2 M, as well as many indicators such as Price To Sales Ratio of 6.5, Dividend Yield of 0.0 or PTB Ratio of 4.47. Immunocore financial statements analysis is a perfect complement when working with Immunocore Holdings Valuation or Volatility modules.
  
Build AI portfolio with Immunocore Stock
Check out the analysis of Immunocore Holdings Correlation against competitors.
To learn how to invest in Immunocore Stock, please use our How to Invest in Immunocore Holdings guide.

Immunocore Holdings Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Other Current Liabilities224 M213.4 M60.8 M
Slightly volatile
Total Current Liabilities256.2 M244 M84.3 M
Slightly volatile
Other Liabilities5.1 M5.3 M20.4 M
Slightly volatile
Net Tangible Assets336.1 M320.1 M185.1 M
Slightly volatile
Accounts Payable30.3 M28.9 M11.3 M
Slightly volatile
Net Receivables100.3 M95.6 M37.7 M
Slightly volatile
Other Stockholder Equity1.4 B1.4 B430.9 M
Slightly volatile
Total Current Assets1.1 B1.1 B379.4 M
Slightly volatile
Property Plant Equipment33.1 M36.4 M24.1 M
Slightly volatile
Total Assets1.2 B1.2 B419.2 M
Slightly volatile
Short and Long Term Debt Total522.5 M497.6 M119.3 M
Slightly volatile
Total Stockholder Equity224.9 M414.8 M148.5 M
Slightly volatile
Property Plant And Equipment Net47.5 M54.9 M33.6 M
Slightly volatile
Cash317.6 M524.1 M226.9 M
Slightly volatile
Non Current Assets Total63.4 M91.6 M44.4 M
Slightly volatile
Non Currrent Assets Other20.7 M19.7 M7.1 M
Slightly volatile
Long Term Debt472.1 M449.7 M98.9 M
Slightly volatile
Cash And Short Term Investments990.6 M943.4 M312.6 M
Slightly volatile
Common Stock Shares Outstanding43.2 M57.5 M34.9 M
Slightly volatile
Liabilities And Stockholders Equity1.2 B1.2 B419.2 M
Slightly volatile
Non Current Liabilities Total527.2 M502.1 M161.3 M
Slightly volatile
Total Liabilities783.4 M746.1 M258.3 M
Slightly volatile
Net Invested Capital907.7 M864.5 M251.3 M
Slightly volatile
Property Plant And Equipment Gross124.4 M118.5 M46.1 M
Slightly volatile
Net Working Capital866.6 M825.3 M267.2 M
Slightly volatile
Intangible Assets3513694.6 M
Pretty Stable
Current Deferred Revenue4.6 M4.9 M27.4 M
Slightly volatile
Short and Long Term Debt15.3 M17.2 M18.8 M
Slightly volatile
Short Term Debt1.3 M1.4 M17.7 M
Slightly volatile
Common Stock Total Equity800900982
Slightly volatile
Common Stock128 K155.2 K88.5 K
Slightly volatile
Good Will327.7 K368.6 K402.4 K
Slightly volatile

Immunocore Holdings Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Other Operating Expenses367.1 M349.7 M124.2 M
Slightly volatile
Interest Income30.9 M29.5 M6.5 M
Slightly volatile
Depreciation And Amortization4.5 MM5.9 M
Slightly volatile
Selling General Administrative101.8 M179.1 M70.7 M
Slightly volatile
Total Revenue299.2 M284.9 M90 M
Slightly volatile
Research Development123.2 M204.1 M104.7 M
Slightly volatile
Total Operating Expenses188.5 M340 M157.1 M
Slightly volatile
Reconciled Depreciation5.4 M3.8 M6.5 M
Slightly volatile
Cost Of Revenue7.2 M7.5 M69.3 M
Slightly volatile

Immunocore Holdings Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
DepreciationM3.8 M5.1 M
Slightly volatile
Total Cash From Financing Activities415.2 M395.5 M114.5 M
Slightly volatile
End Period Cash Flow279.5 M524.1 M201 M
Slightly volatile
Stock Based Compensation25.2 M39.3 M13.5 M
Slightly volatile
Begin Period Cash Flow255.2 M509 M179.5 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio6.56.8429.233
Slightly volatile
PTB Ratio4.474.714.3543
Slightly volatile
Days Sales Outstanding134141490
Slightly volatile
Book Value Per Share3.676.493.4641
Slightly volatile
Average Payables8.5 M11.1 M9.7 M
Slightly volatile
Stock Based Compensation To Revenue0.120.1380.16
Slightly volatile
Capex To Depreciation1.161.110.6456
Slightly volatile
PB Ratio4.474.714.3543
Slightly volatile
EV To Sales6.46.7426.0161
Slightly volatile
Payables Turnover0.370.383.4914
Slightly volatile
Sales General And Administrative To Revenue1.592.941.991
Slightly volatile
Research And Ddevelopement To Revenue0.780.822.6166
Slightly volatile
Capex To Revenue0.02280.0240.1034
Slightly volatile
Cash Per Share15.5114.777.1912
Slightly volatile
Days Payables Outstanding1.4 K983734
Slightly volatile
Intangibles To Total Assets0.00.09.0E-4
Slightly volatile
Net Debt To EBITDA0.510.541.8077
Pretty Stable
Current Ratio2.843.943.4864
Pretty Stable
Tangible Book Value Per Share3.676.493.4579
Slightly volatile
Receivables Turnover3.02.682.1192
Slightly volatile
Shareholders Equity Per Share3.676.493.4641
Slightly volatile
Debt To Equity1.221.380.7653
Slightly volatile
Capex Per Share0.110.120.1144
Slightly volatile
Average Receivables25.2 M40.8 M24.4 M
Slightly volatile
Revenue Per Share4.684.461.935
Slightly volatile
Interest Debt Per Share8.548.132.5616
Slightly volatile
Debt To Assets0.20.390.1818
Slightly volatile
Price Book Value Ratio4.474.714.3543
Slightly volatile
Days Of Payables Outstanding1.4 K983734
Slightly volatile
Ebt Per Ebit0.980.860.9193
Pretty Stable
Company Equity Multiplier4.293.223.6772
Very volatile
Long Term Debt To Capitalization0.490.470.2909
Slightly volatile
Total Debt To Capitalization0.440.630.3466
Slightly volatile
Debt Equity Ratio1.221.380.7653
Slightly volatile
Quick Ratio2.863.923.5703
Very volatile
Net Income Per E B T0.810.870.8983
Slightly volatile
Cash Ratio2.261.932.5916
Very volatile
Days Of Sales Outstanding134141490
Slightly volatile
Price To Book Ratio4.474.714.3543
Slightly volatile
Fixed Asset Turnover4.914.672.1502
Slightly volatile
Debt Ratio0.20.390.1818
Slightly volatile
Price Sales Ratio6.56.8429.233
Slightly volatile
Asset Turnover0.160.220.1618
Slightly volatile
Price Fair Value4.474.714.3543
Slightly volatile

Immunocore Holdings Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap3.2 BB1.5 B
Slightly volatile
Enterprise Value2.8 B2.7 B1.4 B
Slightly volatile

Immunocore Fundamental Market Drivers

Immunocore Upcoming Events

6th of March 2024
Upcoming Quarterly Report
View
8th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
6th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Immunocore Holdings Financial Statements

Immunocore Holdings shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Immunocore Holdings investors may analyze each financial statement separately, they are all interrelated. The changes in Immunocore Holdings' assets and liabilities, for example, are also reflected in the revenues and expenses on on Immunocore Holdings' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue4.9 M4.6 M
Total Revenue284.9 M299.2 M
Cost Of Revenue7.5 M7.2 M
Stock Based Compensation To Revenue 0.14  0.12 
Sales General And Administrative To Revenue 2.94  1.59 
Research And Ddevelopement To Revenue 0.82  0.78 
Capex To Revenue 0.02  0.02 
Revenue Per Share 4.46  4.68 
Ebit Per Revenue(0.20)(0.21)

Pair Trading with Immunocore Holdings

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Immunocore Holdings position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Immunocore Holdings will appreciate offsetting losses from the drop in the long position's value.

Moving against Immunocore Stock

  0.52KRRO Frequency TherapeuticsPairCorr
  0.34IMMP Immutep Ltd ADRPairCorr
The ability to find closely correlated positions to Immunocore Holdings could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Immunocore Holdings when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Immunocore Holdings - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Immunocore Holdings to buy it.
The correlation of Immunocore Holdings is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Immunocore Holdings moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Immunocore Holdings moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Immunocore Holdings can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Additional Tools for Immunocore Stock Analysis

When running Immunocore Holdings' price analysis, check to measure Immunocore Holdings' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunocore Holdings is operating at the current time. Most of Immunocore Holdings' value examination focuses on studying past and present price action to predict the probability of Immunocore Holdings' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunocore Holdings' price. Additionally, you may evaluate how the addition of Immunocore Holdings to your portfolios can decrease your overall portfolio volatility.